Enhanced Anti-MICA Antigen Binding Fragments and Fusion Molecules for Cancer Immunotherapy
Legal Citation
Summary of the Inventive Concept
This inventive concept introduces a suite of improvements to anti-MICA antigen binding fragments and fusion molecules, enhancing their binding affinity, stability, and efficacy in cancer immunotherapy.
Background and Problem Solved
The original patent disclosed anti-MICA antigen binding fragments and fusion molecules for cancer immunotherapy. However, these molecules had limitations in terms of binding affinity, stability, and efficacy. The new inventive concept addresses these limitations by introducing direct improvements and enhancements, resulting in more effective and efficient cancer treatment.
Detailed Description of the Inventive Concept
The new inventive concept comprises four key aspects: 1) a system for detecting MICA-expressing cells using a fusion molecule with enhanced binding affinity, 2) a method for enhancing the cytotoxic activity of T-cells against MICA-expressing cancer cells using a bi-specific T-cell engager, 3) a CAR-T cell therapy with improved stability and folding of the chimeric antigen receptor, and 4) a system for monitoring the efficacy of anti-MICA CAR-T cell therapy using a biosensor. These improvements enable more accurate detection, enhanced treatment efficacy, and better monitoring of treatment outcomes.
Novelty and Inventive Step
The new inventive concept introduces novel and non-obvious improvements to the original patent, including enhanced binding affinity, improved stability and folding, and innovative biosensor technology. These advancements provide a significant step forward in cancer immunotherapy, enabling more effective and efficient treatment of MICA-expressing cancer cells.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different types of fusion molecules, modifying the bi-specific T-cell engager to target other cancer markers, or developing new biosensor technologies to monitor treatment outcomes. These variations would ensure broad conceptual coverage and enable adaptation to different therapeutic contexts.
Potential Commercial Applications and Market
The enhanced anti-MICA antigen binding fragments and fusion molecules have significant commercial potential in the cancer immunotherapy market. The inventive concept could be licensed to biotech companies, used to develop new cancer therapies, or integrated into existing treatment regimens to improve patient outcomes.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunotherapy, molecular biology, and cancer treatment technologies involving chimeric antigen receptors (CARs) and targeted cellular therapies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with a PhD in molecular biology or immunology, experienced in CAR-T cell design, antibody engineering, and cancer immunotherapy techniques, with knowledge of protein engineering and cellular targeting strategies
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core technology, utilizing standard molecular biology techniques to enhance anti-MICA CAR-T cell performance. The disclosed improvements follow established engineering principles for optimizing cellular therapies, involving well-known strategies such as modifying binding domains, improving protein stability, and developing companion diagnostic technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,571 |
|---|---|
| Title | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| Assignee(s) | The Trustees of Dartmouth College |